Mitchell C. Posner to Pancreatic Neoplasms
This is a "connection" page, showing publications Mitchell C. Posner has written about Pancreatic Neoplasms.
Connection Strength
2.467
-
Perioperative Gemcitabine?+?Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Ann Surg Oncol. 2019 Dec; 26(13):4489-4497.
Score: 0.471
-
Research gaps in pancreatic cancer research and comparative effectiveness research methodologies. Cancer Treat Res. 2015; 164:165-94.
Score: 0.342
-
More harm than good? Ann Surg Oncol. 2014 Sep; 21(9):2817-9.
Score: 0.331
-
Electronic synoptic operative reporting for pancreatic resection. J Am Coll Surg. 2011 Mar; 212(3):425-6; author reply 426.
Score: 0.262
-
Total Pancreatectomy with Islet Autotransplantation for the Ampullary Cancer. A Case Report. J Gastrointest Cancer. 2019 09; 50(3):543-547.
Score: 0.118
-
Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. J Surg Oncol. 2018 Mar; 117(3):354-362.
Score: 0.104
-
Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance. Oncotarget. 2016 Jul 12; 7(28):43039-43051.
Score: 0.095
-
Management of the pancreatic stump following pancreaticoduodenectomy. Br J Surg. 1995 Dec; 82(12):1590-7.
Score: 0.091
-
Geriatric assessment improves prediction of surgical outcomes in older adults undergoing pancreaticoduodenectomy: a prospective cohort study. Ann Surg. 2014 May; 259(5):960-5.
Score: 0.082
-
National assessment of margin status as a quality indicator after pancreatic cancer surgery. Ann Surg Oncol. 2014 Apr; 21(4):1067-74.
Score: 0.080
-
Supportive care considerations during concurrent chemoradiotherapy for pancreatic adenocarcinoma: lessons learned from clinical experience. Am J Clin Oncol. 2013 Dec; 36(6):637-43.
Score: 0.079
-
Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 2013 Aug; 20(8):2787-95.
Score: 0.075
-
EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study. Gastrointest Endosc. 2012 Feb; 75(2):332-8.
Score: 0.070
-
Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial. Ann Surg Oncol. 2011 Feb; 18(2):337-44.
Score: 0.063
-
Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031. Ann Oncol. 2011 Feb; 22(2):348-54.
Score: 0.063
-
Hand-assisted laparoscopic surgery for cancer. Cancer J. 2002 Mar-Apr; 8(2):144-53.
Score: 0.035
-
Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: a University of Chicago phase II consortium study. Ann Oncol. 1998 Sep; 9(9):1035-7.
Score: 0.028
-
A prospective randomized trial of total parenteral nutrition after major pancreatic resection for malignancy. Ann Surg. 1994 Oct; 220(4):436-41; discussion 441-4.
Score: 0.021
-
Neoadjuvant therapy for unresectable pancreatic adenocarcinoma. Arch Surg. 1993 May; 128(5):559-64.
Score: 0.019
-
Preemptive surgery for premalignant foregut lesions. J Gastrointest Surg. 2009 Oct; 13(10):1874-87.
Score: 0.015
-
Cyclopamine increases the cytotoxic effects of paclitaxel and radiation but not cisplatin and gemcitabine in Hedgehog expressing pancreatic cancer cells. Cancer Chemother Pharmacol. 2006 Dec; 58(6):765-70.
Score: 0.012
-
Ionizing radiation activates late herpes simplex virus 1 promoters via the p38 pathway in tumors treated with oncolytic viruses. Cancer Res. 2005 Oct 15; 65(20):9479-84.
Score: 0.011